Propriétés différentielles des inhibiteurs de Janus Kinase dans le traitement des maladies inflammatoires à médiation immunitaire
Rheumatology (Oxford) 2023;63(2):298–308 doi 10.1093/rheumatology/kead448
JAKis differ in structure, which affects their inhibitory concentration for different JAKs.
This review by Taylor, et al. compares the pharmacological profiles of JAKis, including abrocitinib, baricitinib, filgotinib, peficitinib, tofacitinib, and upadacitinib.
Baricitinib and tofacitinib are not associated with notable haematological changes versus other JAKis. Furthermore, differences in JAKi metabolism and elimination result in differing recommendations and dose modifications in patients with renal and hepatic impairments.
Keywords:
